Bicara Therapeutics Inc. (BCAX) Price & Analysis

Compare

53 Followers

BCAX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$7.80 - $28.09

Previous CloseN/A

Volume80.52K

Average Volume (3M)538.09K

Market Cap

$626.62M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.70

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding54,536,217

10 Day Avg. Volume290,893

30 Day Avg. Volume538,091

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$32.60

Price Target Upside181.03% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Efficacy Of TreatmentThe combination of ficerafusp alfa and Keytruda showed a 54% confirmed overall response rate and a 21% complete response rate, which is superior to other treatments in similar patient populations.

Survival RatesFicerafusp alfa + Keytruda demonstrated a median progression-free survival of 9.9 months and a median overall survival of 21.3 months, which is notable compared to other treatments.

Bears Say

Development StatusFicera is still behind in development, with an ongoing Ph2 study and unclear Phase 3 dose.

Stock Price MovementShares are down significantly intraday and could continue to move down modestly into the ASCO presentation.

Bicara Therapeutics Inc. News

Bicara Therapeutics Elects New Directors at Annual Meeting

The latest announcement is out from Bicara Therapeutics Inc. ( ($BCAX) ). On June 9, 2025, Bicara Therapeutics...

2M ago

BCAX

Bicara Therapeutics Expands Boston Headquarters with New Lease

An update from Bicara Therapeutics Inc. ( ($BCAX) ) is now available. On June 2, 2025, Bicara Therapeutics...

2M ago

BCAX

Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: Analyst Reiterates Buy Rating with Strong Clinical Results and $41 Price Target

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Bicara Therapeutics Inc. (BCAX – Research...

2M ago

BCAX

Promising Efficacy of Bicara Therapeutics’ Ficera in Combination with Pembro for HPV-Negative HNSCC Justifies Buy Rating

Analyst Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report)...

2M ago

BCAX

Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

It’s time for a roundup of all the biggest stock market stories traders need to catch up on from Friday morning! ...

2M ago

ADI

BAH

Wells upgrades Bicara to Equal Weight with thesis played out

Wells Fargo upgraded Bicara Therapeutics (BCAX) to Equal Weight from Underweight with an unchanged price target of $8....

2M ago

BCAX

Bicara Therapeutics upgraded to Equal Weight from Underweight at Wells Fargo

Wells Fargo analyst Eva Fortea Verdejo upgraded Bicara Therapeutics (BCAX) to Equal Weight from Underweight with an unchanged...

2M ago

BCAX

Stocks slide as Trump threatens new tariffs against EU and Apple: Morning Buzz

Stock futures were flat in early morning trading, but took a turn for the worse after President Donald...

2M ago

BAH

Why Is Bicara Therapeutics Stock (BCAX) Down 30% Today?

Bicara Therapeutics stock plummeted on Friday as BCAX investors reacted negatively to the company’s latest clinical trial data. ...

2M ago

BCAX

Promising Efficacy and Survival Data Drive Buy Rating for Bicara Therapeutics

Stifel Nicolaus analyst Stephen Willey has maintained their bullish stance on BCAX stock, giving a Buy rating yesterday....

2M ago

BCAX

Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa in HPV-Negative HNSCC Drives Buy Rating

Analyst Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report)...

2M ago

BCAX

Closing Bell Movers: Deckers falls 15% on weak guidance; Nuclear names rally

In the opening hour of the evening session, U.S. equity futures are down marginally – S&P 500 is...

2M ago

NNE

SMR

Bicara Therapeutics publishes updated data from Phase 1/1b trial of Ficerafusp

The company states: “Bicara Therapeutics (BCAX) announced the publication of an abstract with updated interim data from the...

2M ago

BCAX

Bicara Therapeutics Inc.: Promising Clinical Trials and Stable Financial Outlook Support Buy Rating

Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report)...

3M ago

BCAX

BCAX FAQ

What was Bicara Therapeutics Inc.’s price range in the past 12 months?

Bicara Therapeutics Inc. lowest stock price was $7.80 and its highest was $28.09 in the past 12 months.

What is Bicara Therapeutics Inc.’s market cap?

Bicara Therapeutics Inc.’s market cap is $626.62M.

When is Bicara Therapeutics Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Bicara Therapeutics Inc.’s earnings last quarter?

Currently, no data Available

Is Bicara Therapeutics Inc. overvalued?

According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bicara Therapeutics Inc. pay dividends?

Bicara Therapeutics Inc. does not currently pay dividends.

What is Bicara Therapeutics Inc.’s EPS estimate?

Bicara Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bicara Therapeutics Inc. have?

Bicara Therapeutics Inc. has 54,536,217 shares outstanding.

What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?

Currently, no hedge funds are holding shares in BCAX

Bicara Therapeutics Inc. Stock Smart Score

Underperform

Company Description

Bicara Therapeutics Inc.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Bicara Therapeutics Inc. (BCAX) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

BCAX Earnings Data >

BCAX Stock 12 Month Forecast

Average Price Target

$32.60

▲(181.03%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","28":"$28","49":"$49","17.5":"$17.5","38.5":"$38.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,17.5,28,38.5,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.9,12.830769230769231,15.761538461538462,18.692307692307693,21.623076923076923,24.553846153846155,27.484615384615388,30.415384615384617,33.34615384615385,36.276923076923076,39.20769230769231,42.13846153846154,45.06923076923077,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.9,11.646153846153847,13.392307692307693,15.13846153846154,16.884615384615387,18.630769230769232,20.376923076923077,22.123076923076923,23.86923076923077,25.61538461538462,27.361538461538466,29.10769230769231,30.853846153846156,{"y":32.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.9,9.753846153846155,9.607692307692307,9.461538461538462,9.315384615384616,9.169230769230769,9.023076923076923,8.876923076923077,8.73076923076923,8.584615384615384,8.438461538461539,8.292307692307691,8.146153846153846,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.41,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.41,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.41,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.43,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.43,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.62,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.3,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.9,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >